Credit Suisse’s Foghorn Therapeutics FHTX Stock Holding History
Bought
Maintained
Sold
Other funds holding FHTX
FP
AG
EC
RJA
DM
AI
Credit Suisse's FHTX Position: Q1 2023 in Review
Credit Suisse sold out of Foghorn Therapeutics (FHTX) in Q1 2023, closing a stake of 1 share — an estimated $6 sold.
Credit Suisse first reported a position in FHTX in Q2 2022 and held it in 3 quarters. The position peaked at $1K in Q3 2022. 60 funds tracked by Wall St. Rank hold FHTX as of Q1 2023.
- Credit Suisse reported no remaining Foghorn Therapeutics position as of Q1 2023 after selling out during the quarter.
- Credit Suisse sold 1 Foghorn Therapeutics share in Q1 2023, an estimated $6.
- Credit Suisse first reported a position in Foghorn Therapeutics in Q2 2022 and held it in 3 quarters.
- Credit Suisse's Foghorn Therapeutics position peaked at $1K in Q3 2022.
- 60 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2023.
Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.